Q4 2024 Earnings Call Transcript February 6, 2025 Neurocrine Biosciences, Inc. misses on earnings expectations. Reported EPS ...

Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (Processa or the Company), a clinical-stage pharmaceutical company focused on ...

BridgeBio could be an acquisition target, but current financial challenges and competition suggest a "Hold" rating until ...

The company is currently preparing for Phase III trials to further assess the efficacy and safety of the agent in identifying active inflammation in individuals with Crohn's disease. Credit: ...

JMP Securities reiterated its Market Outperform rating and $78.00 price target for Cytokinetics shares (NASDAQ:CYTK). This affirmation comes despite the stock experiencing a significant drop on ...

Nancy A. Grygiel, Senior Vice President and Chief Compliance Officer at Amgen Inc . (NASDAQ:AMGN), recently sold shares of the company's common stock. According to a filing with the Securities and ...

Brett P. Monia, the Chief Executive Officer of Ionis Pharmaceuticals Inc. (NASDAQ:IONS), sold 38,843 shares of the company's common stock on February 4, according to a recent SEC filing. The sale ...

MOUNTAIN VIEW, Calif. - RenovoRx , Inc. (NASDAQ:RNXT), a $35.7 million market cap developer of targeted oncology therapies, has initiated an underwritten public offering of its common stock and ...

But this week, the stock jumped again after Amgen issued a strong financial update Tuesday. Its rise helped push up the S&P ...

Supernus Pharmaceuticals' FDA approval for ONAPGO in Parkinson's Disease offers optimism despite past challenges, with a ...

Tobacco firm Philip Morris’ 2025 earnings guidance easily topped expectations, overshadowing the fourth-quarter report.